John P. Mueller

发表

Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases

S. McLeod, R. Tommasi, M. Sacco, 2020, Journal of medicinal chemistry.

ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii

D. Ehmann, S. McLeod, Camilo Velez-Vega, 2017, Nature Microbiology.

Challenges and opportunities in the discovery, development, and commercialization of pathogen-targeted antibiotics.

R. Tommasi, M. Perros, John P. Mueller, 2021, Drug discovery today.

Susceptibility Trends of Zoliflodacin against Multidrug-Resistant Neisseria gonorrhoeae Clinical Isolates in Nanjing, China, 2014 to 2018

C. Genco, Baoxi Wang, X. Su, 2021 .

Susceptibility Trends of Zoliflodacin against Multidrug-Resistant Neisseria gonorrhoeae Clinical Isolates in Nanjing, China, 2014 to 2018

P. Rice, C. Genco, Baoxi Wang, 2020, Antimicrobial Agents and Chemotherapy.

In Vitro Antibacterial Activity and In Vivo Efficacy of Sulbactam-Durlobactam against Pathogenic Burkholderia Species

J. Lipuma, R. Panchal, K. Papp-Wallace, 2020, Antimicrobial Agents and Chemotherapy.

Thorough QT Study To Evaluate the Effect of Zoliflodacin, a Novel Therapeutic for Gonorrhea, on Cardiac Repolarization in Healthy Adults

J. O'Donnell, M. Kankam, G. Saviolakis, 2021, Antimicrobial agents and chemotherapy.

Single-dose Pharmacokinetics , Excretion , and Metabolism of Zoliflodacin , a 1 Novel Spiropyrimidinetrione Antibiotic , in Healthy Volunteers 2

K. Vishwanathan, J. O’Donnell, John P. Mueller, 2018 .

In Vitro Antibacterial Activity of AZD0914, a New Spiropyrimidinetrione DNA Gyrase/Topoisomerase Inhibitor with Potent Activity against Gram-Positive, Fastidious Gram-Negative, and Atypical Bacteria

G. Basarab, M. Huband, P. Miller, 2014, Antimicrobial Agents and Chemotherapy.

Novel monobactams utilizing a siderophore uptake mechanism for the treatment of gram-negative infections.

V. Shanmugasundaram, M. Huband, T. Harris, 2012, Bioorganic & medicinal chemistry letters.

Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols.

T. Gootz, M. Huband, S. J. Brickner, 2011, ACS medicinal chemistry letters.

-Activated SJL/J Astrocytes γ Cells by IFN- T B7-1-Dependent Activation of Encephalitogenic Presentation of Proteolipid Protein Epitopes and

L. Matis, S. Miller, K. Gordon, 2013 .

J Astrocytes γ Cells by IFN-TB 7-1-Dependent Activation of Encephalitogenic Presentation of Proteolipid Protein Epitopes and and

L. Matis, S. Miller, K. Gordon, 1998 .

Effective Antigen-Specific Immunotherapy in the Marmoset Model of Multiple Sclerosis

Joseph Frank, L. Matis, A. Lobito, 2001, The Journal of Immunology.

The Bacillus subtilis menCD promoter is responsive to extracellular pH

H. Taber, K. Hill, John P. Mueller, 2004, Archives of Microbiology.

Zoliflodacin: An oral spiropyrimidinetrione antibiotic for the treatment of Neisseria gonorrhoeae, including multi-drug resistant isolates.

P. Bradford, Alita A. Miller, J. O’Donnell, 2020, ACS infectious diseases.

Characterization of the Novel DNA Gyrase Inhibitor AZD0914: Low Resistance Potential and Lack of Cross-Resistance in Neisseria gonorrhoeae

M. Huband, R. Alm, R. Mclaughlin, 2014, Antimicrobial Agents and Chemotherapy.

Discovery and structural characterization of an allosteric inhibitor of bacterial cis‐prenyltransferase

K. Fennell, D. Danley, B. Chrunyk, 2015, Protein Science.

Discovery of efficacious Pseudomonas aeruginosa-targeted siderophore-conjugated monocarbams by application of a semi-mechanistic pharmacokinetic/pharmacodynamic model.

D. Ehmann, V. Galullo, Pratik Bhagunde, 2015, Journal of medicinal chemistry.

Corrigendum: Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases

M. Gowravaram, G. Basarab, V. Galullo, 2015, Scientific reports.

Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases

M. Gowravaram, G. Basarab, V. Galullo, 2015, Scientific Reports.

Pyridone-conjugated monobactam antibiotics with gram-negative activity.

V. Shanmugasundaram, M. Huband, T. Harris, 2013, Journal of medicinal chemistry.

Pharmacokinetic/Pharmacodynamic Determination and Preclinical Pharmacokinetics of the β-Lactamase Inhibitor ETX1317 and Its Orally Available Prodrug ETX0282

Angela Tanudra, R. Tommasi, April Chen, 2020, ACS infectious diseases.

In vitro Characterization of ETX1317, a broad-spectrum β-lactamase inhibitor that restores and enhances β-lactam activity against multidrug resistant Enterobacteriales, including carbapenem-resistant strains.

S. McLeod, R. Tommasi, Alita A. Miller, 2020, ACS infectious diseases.

Corrigendum: Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases

M. Gowravaram, G. Basarab, V. Galullo, 2015, Scientific Reports.

Immune tolerance mediated by recombinant proteolipid protein prevents experimental autoimmune encephalomyelitis

L. Matis, J. Wilkins, C. Raine, 1997, Journal of Neuroimmunology.

High In Vitro Activity of the Novel Spiropyrimidinetrione AZD0914, a DNA Gyrase Inhibitor, against Multidrug-Resistant Neisseria gonorrhoeae Isolates Suggests a New Effective Option for Oral Treatment of Gonorrhea

M. Unemo, M. Ohnishi, M. Huband, 2014, Antimicrobial Agents and Chemotherapy.

Characterization of the novel DNA gyrase inhibitor AZD 0914 : Low resistance potential 1 and lack of cross-resistance in Neisseria gonorrhoeae . 2 3 4 5 6

M. Huband, R. Alm, James D. Whiteaker, 2014 .

Susceptibility trends of zoliflodacin against multidrug-resistant Neisseria gonorrhoeae clinical isolates in Nanjing, China (2014-2018)

P. Rice, C. Genco, Baoxi Wang, 2020, bioRxiv.

Multidrug-Resistant Neisseria gonorrhoeae Isolates from Nanjing, China, Are Sensitive to Killing by a Novel DNA Gyrase Inhibitor, ETX0914 (AZD0914)

P. Rice, R. Alm, Bao-xi Wang, 2015, Antimicrobial Agents and Chemotherapy.

PORCINE VASCULAR CELL ADHESION MOLECULE (VCAM) MEDIATES ENDOTHELIAL CELL ADHESION TO HUMAN T CELLS

L. Matis, M. Evans, R. Rother, 1995, Transplantation.

Clinically Relevant Gram-Negative Resistance Mechanisms Have No Effect on the Efficacy of MC-1, a Novel Siderophore-Conjugated Monocarbam

L. Aschenbrenner, C. McPherson, M. Lemmon, 2012, Antimicrobial Agents and Chemotherapy.

Single-Dose Pharmacokinetics, Excretion, and Metabolism of Zoliflodacin, a Novel Spiropyrimidinetrione Antibiotic, in Healthy Volunteers

K. Vishwanathan, V. Hosagrahara, J. O’Donnell, 2018, Antimicrobial Agents and Chemotherapy.

In vitro growth of multidrug-resistant Neisseria gonorrhoeae isolates is inhibited by ETX0914, a novel spiropyrimidinetrione.

J. Papp, R. Kirkcaldy, John P. Mueller, 2016, International journal of antimicrobial agents.

CJ-21,058, a new SecA inhibitor isolated from a fungus.

Y. Sugie, F. Dib-Hajj, H. Nishida, 2002, The Journal of antibiotics.

Determination of MIC Quality Control Ranges for the Novel Gyrase Inhibitor Zoliflodacin

M. Huband, P. Bradford, M. Traczewski, 2019, Journal of Clinical Microbiology.

Characterization of the aqueous iron(III) chelation chemistry of a potential Trojan Horse antimicrobial agent: chelate structure, stability and pH dependent speciation

J. Harrington, M. Flanagan, A. L. Crumbliss, 2012, BioMetals.

SAR and Structural Analysis of Siderophore-Conjugated Monocarbam Inhibitors of Pseudomonas aeruginosa PBP3.

A. Ferguson, Kerry E. Murphy-Benenato, Ning Gao, 2015, ACS medicinal chemistry letters.

Effect of food on the pharmacokinetics of zoliflodacin granules for oral suspension: Phase I open‐label randomized cross‐over study in healthy subjects

E. Bettiol, E. Alirol, J. Gillon, 2023, Clinical and translational science.

In vitro growth of multidrug-resistant Neisseria gonorrhoeae isolates is inhibited by ETX0914, a novel spiropyrimidinetrione.

J. Papp, R. Kirkcaldy, John P. Mueller, 2016, International Journal of Antimicrobial Agents.